Natera agreed to acquire Foresight Diagnostics for $275 million up front plus up to $175 million in earnouts to integrate PhasED‑Seq phased‑variant MRD technology into its Signatera platform. Natera said the acquisition immediately strengthens lymphoma MRD sensitivity and accelerates planned commercial and clinical MRD deployments across solid tumors. The company highlighted expected synergies for reimbursement and trial use while noting an enhanced platform will be available for research use immediately, with clinical launch targeted in 2026. Investors and analysts flagged the move as a strategic step to consolidate MRD capabilities in precision oncology.